MURA Mural Oncology plc revenue, earnings and financials
For the quarter ended September 30, 2025, Mural Oncology plc reported revenue of n/a, net income of −$3.71M and diluted EPS of −$0.21; for the fiscal year ended December 2024 revenue was n/a.
MURA annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$138M, net income −$129M (margin n/a), EPS −$7.58
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$196M, net income −$207M (margin n/a), EPS −$12.43
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$185M, net income −$190M (margin n/a), EPS −$11.37
MURA quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.71M, EPS −$0.21
- Quarter ended Jun 30, 2025: revenue n/a, net income −$48.0M, EPS −$2.78
- Quarter ended Mar 31, 2025: revenue n/a, net income −$33.1M, EPS −$1.93
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$34.3M, EPS −$2.01
- Quarter ended Sep 30, 2024: revenue n/a, net income −$31.8M, EPS −$1.87
- Quarter ended Jun 30, 2024: revenue n/a, net income −$31.6M, EPS −$1.86
- Quarter ended Mar 31, 2024: revenue n/a, net income −$30.9M, EPS −$1.84
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$59.5M, EPS −$3.57
- Quarter ended Sep 30, 2023: revenue n/a, net income −$51.3M, EPS −$3.07
- Quarter ended Jun 30, 2023: revenue n/a, net income −$49.8M, EPS −$3.01
- Quarter ended Mar 31, 2023: revenue n/a, net income −$46.8M, EPS −$2.78
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$48.6M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$50.6M, EPS −$3.03
- Quarter ended Jun 30, 2022: revenue n/a, net income −$43.3M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$47.3M, EPS n/a
MURA cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$129M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$194M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$169M, share buybacks n/a
MURA balance sheet
- Sep 30, 2025: cash $58.9M, total assets $65.8M, total liabilities $10.6M, shareholders' equity $55.2M
- Jun 30, 2025: cash $77.1M, total assets $87.6M, total liabilities $28.8M, shareholders' equity $58.8M
- Mar 31, 2025: cash $107M, total assets $132M, total liabilities $24.2M, shareholders' equity $108M
- Dec 31, 2024: cash $115M, total assets $169M, total liabilities $28.9M, shareholders' equity $141M
- Sep 30, 2024: cash $111M, total assets $203M, total liabilities $29.1M, shareholders' equity $174M
- Jun 30, 2024: cash $122M, total assets $235M, total liabilities $30.4M, shareholders' equity $205M
- Mar 31, 2024: cash $107M, total assets $264M, total liabilities $28.6M, shareholders' equity $235M
- Dec 31, 2023: cash $271M, total assets $302M, total liabilities $37.9M, shareholders' equity $264M
Is MURA profitable?
No. Mural Oncology plc lost $119M over the last four quarters.
What is MURA's EPS?
Diluted earnings per share over the last four quarters were −$6.93; −$0.21 in the latest quarter.